Chapter 1: Muscular Atrophy in Children
Introduction to Muscular Atrophy
Classification of Muscular Atrophy
- Neurogenic atrophy: Results from damage to the nerve innervating muscle (e.g., spinal muscular atrophy, peripheral neuropathies) 3.
- Myogenic atrophy: Primary muscle disease causing intrinsic muscle fiber degeneration (e.g., muscular dystrophies, congenital myopathies) 1, 2.
- Disuse/physiologic atrophy: Caused by underuse of skeletal muscle from immobilization or reduced physical activity.
Etiology and Causes of Muscular Atrophy
- Neurogenic causes: Anterior horn cell disease, peripheral neuropathies, and spinal cord injury with tethered cord syndrome 3.
- Myogenic causes: Muscular dystrophies, congenital myopathies, myofibrillar myopathies, and mitochondrial myopathies 1, 2, 4, 5.
- Disuse and immobilization: Prolonged bed rest or immobilization, casting or orthopedic immobilization, and reduced physical activity from any chronic illness.
- Metabolic, endocrine, and nutritional causes: Endocrine myopathies, metabolic causes, and nutritional deficiencies 1, 6.
Clinical Features of Muscular Atrophy
- Proximal muscle weakness: Difficulty rising from the floor, climbing stairs, and waddling gait 1.
- Distal muscle weakness: Weakness in the hands and feet, leading to difficulties with fine motor activities and walking 5.
- Facial and bulbar involvement: Facial weakness, ptosis, and bulbar muscle dysfunction, leading to difficulties with swallowing and speech 7.
- Gowers sign: A classic maneuver indicating proximal lower extremity weakness, where the child uses their hands to "climb up" their own legs when rising from the floor 1.
Investigations for Muscular Atrophy
- Creatine kinase (CK) levels: Elevated CK levels can indicate muscle damage or disease 8, 9.
- Electromyography (EMG) and nerve conduction studies (NCS): Help differentiate between myopathic and neurogenic processes 1, 8.
- Muscle biopsy: The gold standard for confirming diagnosis and subclassification of muscular atrophy 1, 8.
- Genetic testing: Essential for identifying the underlying genetic cause of muscular atrophy 1, 4, 5.
Management and Treatment of Muscular Atrophy
- Supportive care: Respiratory support, cardiac management, nutritional support, and orthopedic management 7.
- Disease-specific treatment: Treatment for the underlying cause of muscular atrophy, such as corticosteroids for Duchenne muscular dystrophy or exon-skipping therapies for specific mutations 1.
- Physiotherapy and rehabilitation: Essential for maintaining muscle strength and function, and preventing complications such as contractures and scoliosis.
Prognosis and Complications of Muscular Atrophy
- Respiratory failure: A leading cause of morbidity and mortality in children with muscular atrophy 7.
- Cardiac complications: Cardiomyopathy, arrhythmias, and cardiac failure can occur in certain types of muscular atrophy 4, 5.
- Skeletal deformities: Scoliosis, contractures, and foot deformities can occur due to muscle weakness and imbalance.
Recent Advances and Newer Therapies
- Gene therapy: A promising treatment approach for certain types of muscular atrophy, such as spinal muscular atrophy and Duchenne muscular dystrophy 1.
- Exon-skipping therapies: A treatment approach for specific mutations in Duchenne muscular dystrophy 1.
- Improved cardiac management: Earlier initiation of ACE inhibitors and beta-blockers can improve cardiac outcomes in children with muscular atrophy 1.
- Multidisciplinary care models: Coordinated comprehensive care can improve survival and quality of life for children with muscular atrophy 7.
Evaluation and Management of Proximal Muscle Weakness in Children
Diagnostic Approach
- Serum creatine kinase (CK) should be measured first; an elevated CK directs evaluation toward juvenile dermatomyositis, whereas a normal or mildly elevated CK prompts consideration of neurogenic or metabolic myopathies, which are the most common treatable causes in this age group 10.
- CK is elevated in roughly 95 % of inflammatory myopathies and most muscular dystrophies, but may be normal in certain metabolic and mitochondrial myopathies 11.
- AST, ALT, and LDH can be modestly increased due to muscle enzyme release and provide additional diagnostic clues 11.
- Dermatomyositis‑specific skin findings (heliotrope rash, Gottron papules, photosensitive erythema, periungual telangiectasias, calcinosis cutis, and cutaneous vasculitis) are key clinical markers 10, 12.
- Assessment of respiratory and cardiac function is essential because complications markedly affect morbidity and mortality in inflammatory myopathies and muscular dystrophies 10.
Differential Diagnosis by CK Level
- Elevated CK with proximal weakness in a young girl strongly suggests juvenile dermatomyositis, especially when characteristic cutaneous signs are present 10, 12.
- Myositis‑specific autoantibodies (e.g., anti‑Jo‑1, anti‑Mi‑2, anti‑SRP, broader synthetase panel) help define disease subgroups, predict pulmonary and cardiac involvement, and provide prognostic information 10.
- Muscle MRI (T1‑weighted, T2‑weighted, and STIR sequences) should be performed to detect inflammation, guide biopsy site selection, and establish a baseline for monitoring therapeutic response 10, 12.
- When CK is normal or only mildly elevated, spinal muscular atrophy type III must be considered, and electromyography (EMG) with nerve‑conduction studies can differentiate myopathic from neurogenic patterns 12.
- Pompe disease should be screened for in cases of proximal myopathy with respiratory compromise; urine glucose tetrasaccharide (Glc4) is a sensitive biomarker 11.
Treatment Strategies
- First‑line therapy for uncomplicated juvenile dermatomyositis consists of oral prednisone 2 mg/kg/day (maximum 60 mg/day) combined with subcutaneous methotrexate 15 mg/m² weekly started at treatment onset 12.
- Corticosteroids are tapered after 2–4 weeks based on clinical response, as early use of a steroid‑sparing agent reduces long‑term steroid toxicity 12.
- Therapeutic response should be monitored through serial clinical strength examinations, CK measurements, and repeat muscle MRI 10, 12.
- For severe or refractory disease (extensive extramuscular organ involvement or inadequate response), high‑dose intravenous methylprednisolone combined with intravenous immunoglobulin, cyclophosphamide, rituximab, or cyclosporine is recommended 12.
Monitoring, Follow‑up, and Safety
- Routine cardiac screening (annual echocardiography and electrocardiogram) is mandatory because cardiac complications such as cardiomyopathy and arrhythmias are major determinants of outcome in limb‑girdle muscular dystrophy and inflammatory myopathies 10.
- Malignancy screening should be performed in patients with dermatomyositis features, although the risk is lower in juvenile compared with adult disease 10.
Evidence strength for the above recommendations was not explicitly stated in the source material.